Title: 2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018 Document date: 2018_10_25
ID: 60ceejq1_23
Snippet: Six, healthy, middle-aged, male beagles were randomized to receive torsemide (0.1mg/kg PO q12h), furosemide (2.0mg/kg PO q12h), or placebo for 10 days during 3 separate experiments in a cross-over design, each separated by a 10-day washout period. Blood was collected on days 1, 5, and 9 and 24-hour urine samples were collected, ending on days 2, 6, and 10. Serum aldosterone was quantified via liquid chromatography-mass spectrometry (LC-MS)/MS and.....
Document: Six, healthy, middle-aged, male beagles were randomized to receive torsemide (0.1mg/kg PO q12h), furosemide (2.0mg/kg PO q12h), or placebo for 10 days during 3 separate experiments in a cross-over design, each separated by a 10-day washout period. Blood was collected on days 1, 5, and 9 and 24-hour urine samples were collected, ending on days 2, 6, and 10. Serum aldosterone was quantified via liquid chromatography-mass spectrometry (LC-MS)/MS and angiotensin metabolites were quantified with LC-MS/MS and equilibrium analysis (Attoquant Diagnostics, Vienna Austria). Urine aldosterone was quantified via radioimmunoassay (Beckman Coulter) and used to calculate the urine aldosterone-to-creatinine ratio (UAldo:C). After repeated measures analysis and Bonferonni correction, variables with an adjusted P < 0.05 were investigated further, using Tukey';s method.
Search related documents:
Co phrase search for related documents- chromatography mass spectrometry and cross design: 1, 2
- cross design and measure analysis: 1
Co phrase search for related documents, hyperlinks ordered by date